scispace - formally typeset
Open AccessJournal ArticleDOI

Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-γ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase

Reads0
Chats0
TLDR
Proinflammatory cytokines activate β-secretase, and NSAIDs inhibit this effect through PPARγ, and it is observed that the mRNA levels, expression, and enzymatic activity of β- secretase were increased by immunostimulation and normalized by NSAIDs.
Abstract
Long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk for Alzheimer9s disease (AD). To determine the mechanisms by which inflammation affects AD and how NSAIDs protect against it, we stimulated neuroblastoma cells stably transfected with amyloid precursor protein (APP) with proinflammatory cytokines, which increased the secretion of amyloid-β and APP ectodomain. Addition of ibuprofen, indomethacin, peroxisome proliferator-activated receptor-γ (PPARγ) agonists, or cotransfection with PPARγ cDNA reversed this effect. The inhibitory action of ibuprofen and indomethacin was suppressed by PPARγ antagonists. Finally, we observed that the mRNA levels, expression, and enzymatic activity of β-secretase were increased by immunostimulation and normalized by NSAIDs. In conclusion, proinflammatory cytokines activate β-secretase, and NSAIDs inhibit this effect through PPARγ.

read more

Citations
More filters
Journal ArticleDOI

Neuroinflammation in Alzheimer's disease

Michael T. Heneka, +41 more
- 01 Apr 2015 - 
TL;DR: Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction.
Journal ArticleDOI

Innate immune activation in neurodegenerative disease

TL;DR: How the activation of innate immune signalling pathways — in particular, the NOD-, LRR- and pyrin domain-containing 3 (NLRP3) inflammasome — by aberrant host proteins may be a common step in the development of diverse neurodegenerative disorders is discussed.
Journal ArticleDOI

Neuroinflammation in Alzheimer's disease: Current evidence and future directions

TL;DR: This review focuses on neuroinflammation in AD, especially in the earliest stages, a vicious cycle of glial priming, release of pro‐inflammatory factors, and neuronal damage, and the relevance of inflammation as a diagnostic and therapeutic target.
Journal ArticleDOI

Inflammatory processes in Alzheimer's disease.

TL;DR: While inflammation has been thought to arise secondary to degeneration, recent experiments demonstrated that inflammatory mediators may stimulate APP processing by upregulation of beta secretase 1 and therefore are able to establish a vicious cycle.
Journal ArticleDOI

The role of inflammation in Alzheimer's disease.

TL;DR: Increasing amount of data suggest that AChRs and PPARs are involved in AD-induced neuroinflammation and in this regard, future therapy may focus on their specific targeting in the AD brain.
References
More filters
Journal ArticleDOI

PPAR-γ agonists inhibit production of monocyte inflammatory cytokines

TL;DR: Inhibition of cytokine production may help to explain the incremental therapeutic benefit of NSAIDs observed in the treatment of rheumatoid arthritis at plasma drug concentrations substantially higher than are required to inhibit prostaglandin G/H synthase (cyclooxygenase).
Journal ArticleDOI

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease

TL;DR: The data suggest that increased expression of S-100 in Down syndrome, resulting from duplication of the gene on chromosome 21 that encodes the beta subunit ofS-100, may be augmented by elevation of interleukin 1, which may promote the astrogliosis in Alzheimer disease.
Journal ArticleDOI

A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity

TL;DR: It is reported that the NSAIDs ibuprofen, indomethacin and sulindac sulphide preferentially decrease the highly amyloidogenic Aβ42 peptide (the 42-residue isoform of the amyloids-β peptide) produced from a variety of cultured cells by as much as 80%.
Related Papers (5)